Land: Kanada
Språk: engelska
Källa: Health Canada
NIFEDIPINE
BAYER INC
C08CA05
NIFEDIPINE
30MG
TABLET (EXTENDED-RELEASE)
NIFEDIPINE 30MG
ORAL
28/98
Prescription
DIHYDROPYRIDINES
Active ingredient group (AIG) number: 0115253004; AHFS:
APPROVED
1995-02-27
_ADALAT XL Product Monograph_ Page 1 of 40 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ADALAT® XL® Nifedipine extended-release tablets Tablet, 30 mg, oral Bayer Standard Antianginal/Antihypertensive Agent Bayer Inc. 2920 Matheson Boulevard East Mississauga, Ontario L4W 5R6 www.bayer.ca Date of Initial Authorization: March 26, 1992 Date of Revision: June 29, 2023 Submission Control No: 270254 © 2023, Bayer Inc. ®TM see www.bayer.ca/tm-mc. All other trademarks are the property of their respective owners. _ADALAT XL Product Monograph_ Page 2 of 40 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................3 1 INDICATIONS .........................................................................................................................3 1.1 PEDIATRICS........................................................................................................................3 1.2 GERIATRICS ........................................................................................................................3 2 CONTRAINDICATIONS............................................................................................................3 4 DOSAGE AND ADMINISTRATION............................................................................................4 4.1 DOSING CONSIDERATIONS ....................................................................................................4 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT .................................................................4 4.4 ADMINISTRATION................................................................................................................5 4.5 MISSED DOSE ........................................................................ Läs hela dokumentet